AMPAR receptor inhibitors suppress proliferation of human small cell lung cancer cell lines

Small cell lung cancer (SCLC) is a neuroendocrine tumor with poor prognosis. Neuroendocrine tumors possess characteristics of both nerve cells and hormone‐secreting cells; therefore, targeting the neuronal properties of these tumors may lead to the development of new therapeutic options. Among the endogenous signaling pathways in the nervous system, targeting the glutamate pathway may be a useful strategy for glioblastoma treatment. Perampanel, an antagonist of the synaptic glutamate α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole propionic acid receptor (AMPAR), has been reported to be effective in patients with glioblastoma. In this study, we aimed to investigate the antitumor effects of AMPAR antagonists in human SCLC cell lines.

[1]  S. Tariq,et al.  Update 2021: Management of Small Cell Lung Cancer , 2021, Lung.

[2]  Y. Hippo,et al.  Recent Advances in Implantation-Based Genetic Modeling of Biliary Carcinogenesis in Mice , 2021, Cancers.

[3]  A. Nakajima,et al.  Precision modeling of gall bladder cancer patients in mice based on orthotopic implantation of organoid-derived tumor buds , 2021, Oncogenesis.

[4]  T. Kuner,et al.  Glutamatergic synaptic input to glioma cells drives brain tumour progression , 2019, Nature.

[5]  Shawn M. Gillespie,et al.  Electrical and synaptic integration of glioma into neural circuits , 2019, Nature.

[6]  E. Gouaux,et al.  Architecture and subunit arrangement of native AMPA receptors elucidated by cryo-EM , 2019, Science.

[7]  R. Köhling,et al.  AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro , 2019, PloS one.

[8]  F. Kruyt,et al.  Lung cancer stem cells: origin, features, maintenance mechanisms and therapeutic targeting , 2019, Biochemical pharmacology.

[9]  Naoki Nakano,et al.  Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel , 2018, AntiCancer Research.

[10]  Wei Yang,et al.  Knockdown of GluA2 induces apoptosis in non-small-cell lung cancer A549 cells through the p53 signaling pathway. , 2017, Oncology letters.

[11]  P. Wahle,et al.  Ionotropic glutamate receptors: Which ones, when, and where in the mammalian neocortex , 2017, The Journal of comparative neurology.

[12]  S. Lauri,et al.  GluA4 subunit of AMPA receptors mediates the early synaptic response to altered network activity in the developing hippocampus. , 2016, Journal of neurophysiology.

[13]  Takuya Takahashi,et al.  Sustained Enhancement of Lateral Inhibitory Circuit Maintains Cross Modal Cortical Reorganization , 2016, PloS one.

[14]  Johannes E. Schindelin,et al.  The ImageJ ecosystem: An open platform for biomedical image analysis , 2015, Molecular reproduction and development.

[15]  D. Radisky,et al.  Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. , 2014, Cancer research.

[16]  Kazuhisa Takahashi,et al.  Lung cancer stem cells: Tumor biology and clinical implications , 2012, Asia-Pacific journal of clinical oncology.

[17]  H. Friess,et al.  Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras‐MAPK signaling , 2011, International journal of cancer.

[18]  Amanda M. Lauer,et al.  GluA4 is indispensable for driving fast neurotransmission across a high‐fidelity central synapse , 2011, The Journal of physiology.

[19]  H. Fine,et al.  Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas , 2010, Cancer.

[20]  R. Tamura,et al.  A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[21]  T. Mikkelsen,et al.  Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  W. Rzeski,et al.  AMPA antagonists inhibit the extracellular signal regulated kinase pathway and suppress lung cancer growth , 2007, Cancer biology & therapy.

[23]  Y. Yoshida,et al.  Ca2+-Permeable AMPA Receptors Regulate Growth of Human Glioblastoma via Akt Activation , 2007, The Journal of Neuroscience.

[24]  J Cuzick,et al.  Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials , 2007, The Lancet.

[25]  Fiona E. N. LeBeau,et al.  Recruitment of Parvalbumin-Positive Interneurons Determines Hippocampal Function and Associated Behavior , 2007, Neuron.

[26]  René H. Levy,et al.  Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII) , 2007, Epilepsy Research.

[27]  Y. Yoshida,et al.  Blockage of Ca2+-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells , 2002, Nature Medicine.

[28]  I. Greger,et al.  RNA Editing at Arg607 Controls AMPA Receptor Exit from the Endoplasmic Reticulum , 2002, Neuron.

[29]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[30]  M. Farrant,et al.  CNQX increases GABA-mediated synaptic transmission in the cerebellum by an AMPA/kainate receptor-independent mechanism , 2001, Neuropharmacology.

[31]  W. Rzeski,et al.  Glutamate antagonists limit tumor growth , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Zhu,et al.  Postnatal synaptic potentiation: Delivery of GluR4-containing AMPA receptors by spontaneous activity , 2000, Nature Neuroscience.

[33]  R. Wenthold,et al.  Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  H. Monyer,et al.  Glutamate-operated channels: Developmentally early and mature forms arise by alternative splicing , 1991, Neuron.

[35]  B. Sakmann,et al.  A family of AMPA-selective glutamate receptors. , 1990, Science.

[36]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. , 1941, CA: a cancer journal for clinicians.

[37]  J. Luszczki.  Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. , 2009, Pharmacological reports : PR.

[38]  Y. Yoshida,et al.  Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. , 2002, Nature medicine.